SHARP PHILLIP A 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Jan 24, 2025
Insider Transaction Report
Form 4
SHARP PHILIP A
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-01-23−11,250→ 0 totalExercise: $131.21From: 2016-06-01Exp: 2025-06-01→ Common Stock (11,250 underlying) - Exercise/Conversion
Common Stock
2025-01-23$131.21/sh+11,250$1,476,113→ 11,250 total - Sale
Common Stock
2025-01-23$275.00/sh−11,250$3,093,750→ 0 total
Holdings
- 266,899(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.
- [F2]Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
- [F3]This stock option was fully vested and exercisable as of June 1, 2016.